Clinical Trial Update: Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and bioequivalence study comparing Gedeon Richter’s empagliflozin/metformin hydrochloride 12.5 mg/1000 mg film-coated tablets with Synj…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin/metformin hydrochloride 12.5 mg/1000 mg film-coated tablets (empagliflozin/metformin hydrochloride)
• Synjardy 12.5 mg/1000 mg film-coated tablets (empagliflozin/metformin)

Snippet

Sponsor: Gedeon Richter Plc. | Conditions: Diabetes Mellitus Type 2 | Phase 1 | Status: COMPLETED